VolitionRX Ltd (VNRX) Stock Analysis & Investment Frameworks
VolitionRX Ltd (VNRX) stock analysis on Invetso. Review VolitionRX Ltd’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
VolitionRX Ltd Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
VolitionRX Ltd Key Financial Metrics
- Market Cap: $2.17M
- Revenue: $1.73M
- ROE: 77.10%
- ROIC: 5674.42%
- Dividend Yield: N/A
About VolitionRX Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VolitionRX Ltd Investment Frameworks
Invetso analyzes VolitionRX Ltd (VNRX) across the following frameworks:
- VolitionRX Ltd 10Y Growth Potential
- VolitionRX Ltd Scenario Analysis
- VolitionRX Ltd Risks & Opportunities
- VolitionRX Ltd Economic Moat
- VolitionRX Ltd Business Model
- VolitionRX Ltd Management
- VolitionRX Ltd SWOT Analysis
- VolitionRX Ltd Porter's 5 Forces
- VolitionRX Ltd PESTLE Analysis
- VolitionRX Ltd ESG Analysis